capmatinib + neratinib

Capmatinib + neratinib is an investigational oral combination therapy being studied for the treatment of metastatic or locally advanced breast cancer, particularly HER2-positive subtypes. Capmatinib is a selective MET tyrosine kinase inhibitor, while neratinib is an irreversible pan-HER tyrosine kinase inhibitor targeting HER1 (EGFR), HER2, and HER4. The rationale for combining these agents stems from the potential to overcome resistance mechanisms in tumors that involve both MET and HER family signaling pathways. This combination aims to provide enhanced antitumor activity by simultaneously inhibiting multiple oncogenic drivers involved in breast cancer progression[1][2]. Clinical trials are ongoing to evaluate safety and efficacy.

Brand names

NerlynxTabrecta

Other names

neratinib + capmatinib